Novo, Lilly shares sink due to concerns over competition
Hellloooooo. Today, we discuss the FDA’s lack of engagement with critics of MDMA for PTSD therapy. We also highlight a massive veterans study on genomics, and how it illustrates the importance of studying diverse populations. And there’s more.
FDA silent on claims of misconduct in MDMA trials
At last month’s advisory committee meeting about Lykos Therapeutics’ MDMA-assisted therapy, the FDA said that it would investigate allegations of data suppression and misconduct in trials of the treatment.
Read Original Article: Novo, Lilly shares sink due to concerns over competition »
